Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission ...
The life sciences industry is experiencing an identity crisis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback